Jefferies Downgrades NGM Biopharmaceuticals (NGM) to Hold

Jefferies analyst Dennis Ding downgraded NGM Biopharmaceuticals (NASDAQ: NGM) from Buy to Hold with a price target of $4.00 (from $25.00).

For an analyst ratings summary and ratings history on NGM Biopharmaceuticals click here. For more ratings news on NGM Biopharmaceuticals click here.

Shares of NGM Biopharmaceuticals closed at $11.55 yesterday.

You May Also Be Interested In

• JPMorgan Downgrades Grab Holdings Inc. (GRAB) to Underweight, 'Recommend tactical UW on risk of earnings missing expectations'
• CFRA Downgrades Old Dominion Freight Line (ODFL) to Sell
• Stifel Downgrades Darktrace PLC (DARK:LN) to Hold